Dejan Micic

Dejan Micic

Auto-generated profile, based on publicly available information

Dejan Micic

Department of Internal Medicine, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
BCBritt Christensen
Britt Christensen
PGPeter R. Gibson
Peter R. Gibson
DMDejan Micic
Dejan Micic
RCRuben J. Colman
Ruben J. Colman
SGSarah R. Goeppinger
Sarah R. Goeppinger
DRDavid T. Rubin
David T. Rubin

24 August 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DMDejan Micic
Dejan Micic
JGJohn N Gaetano
John N Gaetano
JRJonah N Rubin
Jonah N Rubin
RCRussell D Cohen
Russell D Cohen
Atsushi SakurabaAtsushi Sakuraba
Atsushi Sakuraba
JPJoel Pekow
Joel Pekow
Management of inpatients with inflammatory bowel disease (IBD) requires increasing resources. We aimed to identify factors associated with hospital readmissions among individuals with IBD. We collected data from the Healthcare Cost and Utilization Project Nationwide Readmissions Database 2013. We identified individuals with index hospitalizations for IBD. Patient-specific factors, comorbidities and hospitalization characteristics were extracted for the index hospitalization. We performed logistic regression modeling to create adjusted odds ratios (ORs) for 30-day hospital readmission. Subgroup analysis was performed based on disease type and performance of surgery. We analyzed a total of 55,942 index hospital discharges; 3037 patients (7.0%) were readmitted to the hospital within 30 days. Increasing patient age (> 65: OR: 0.45; 95% CI 0.39–0.53) was associated with a decreased risk of readmission, while a diagnosis of Crohn’s disease (OR: 1.09; 95% CI 1.00–1.18) and male sex (OR: 1.16; 95% CI 1.07–1.25) were associated with an increased risk of readmission. The comorbidities of smoking (OR: 1.09; 95% CI 1.00–1.19), anxiety (OR: 1.17; 95% CI 1.01–1.36) and opioid dependence (OR: 1.40; 95% CI 1.06–1.86) were associated with an increased risk of 30-day readmission. Individual hospitalization characteristics and disease complications were significantly associated with readmission. Performance of a surgery during the index admission was associated with a decreased risk of readmission (OR: 0.57; 95% CI 0.33–0.96). Analyzing data from a US publicly available all-payer inpatient healthcare database, we identified patient and hospitalization risk factors associated with 30-day readmission. Identifying patients at high risk for readmission may allow for interventions during or after the index hospitalization to decrease this risk.

2 March 2021 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
PDF file
ALAustin Lin
Austin Lin
DMDejan Micic
Dejan Micic

19 August 2022 in Viruses
Verified
Journal Article
Open access
PDF file
Atsushi SakurabaAtsushi Sakuraba
Atsushi Sakuraba
ALAlexander Luna
Alexander Luna
DMDejan Micic
Dejan Micic
Solid organ transplant (SOT) recipients are at greater risk of coronavirus disease 2019 (COVID-19) and have attenuated response to vaccinations. In the present meta-analysis, we aimed to evaluate the serologic response to the COVID-19 vaccine in SOT recipients. A search of electronic databases was conducted to identify SOT studies that reported the serologic response to COVID-19 vaccination. We analyzed 44 observational studies including 6158 SOT recipients. Most studies were on mRNA vaccination (mRNA-1273 or BNT162b2). After a single and two doses of vaccine, serologic response rates were 8.6% (95% CI 6.8–11.0) and 34.2% (95% CI 30.1–38.7), respectively. Compared to controls, response rates were lower after a single and two doses of vaccine (OR 0.0049 [95% CI 0.0021–0.012] and 0.0057 [95% CI 0.0030–0.011], respectively). A third dose improved the rate to 65.6% (95% CI 60.4–70.2), but in a subset of patients who had not achieved a response after two doses, it remained low at 35.7% (95% CI 21.2–53.3). In summary, only a small proportion of SOT recipients achieved serologic response to the COVID-19 mRNA vaccine, and that even the third dose had an insufficient response. Alternative strategies for prophylaxis in SOT patients need to be developed. Key Contribution: In this meta-analysis that included 6158 solid organ transplant recipients, the serologic response to the COVID-19 vaccine was extremely low after one (8.6%) and two doses (34.2%). The third dose of the vaccine improved the rate only to 66%, and in the subset of patients who had not achieved a response after two doses, it remained low at 36%. The results of our study suggest that a significant proportion of solid organ transplant recipients are unable to achieve a sufficient serologic response after completing not only the two series of vaccination but also the third booster dose. There is an urgent need to develop strategies for prophylaxis including modified vaccine schedules or the use of monoclonal antibodies in this vulnerable patient population.

11 May 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
FPFrances Puello
Frances Puello
EWElizabeth Wall
Elizabeth Wall
JHJean Herlitz
Jean Herlitz
ELEdward S. Lozano
Edward S. Lozano
CSCarol Semrad
Carol Semrad
DMDejan Micic
Dejan Micic

1 April 2020 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
DMDejan Micic
Dejan Micic
VRVijaya L. Rao
Vijaya L. Rao
CSCarol E. Semrad
Carol E. Semrad